Lau Kimberly M, Saunders Ila M, Sacco Assuntina G, Barnachea Linda C
Department of Pharmacy, University of California San Diego Health, La Jolla, CA, USA.
Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
J Oncol Pharm Pract. 2020 Sep;26(6):1390-1396. doi: 10.1177/1078155219897129. Epub 2020 Jan 14.
Head and neck cancers (HNC) are a complex and heterogeneous group of cancers, often necessitating a multidisciplinary approach across the care continuum. Oncology pharmacists are uniquely qualified to play a vital role on a multidisciplinary team and provide specialized care to optimize medication therapy.
This was a retrospective chart review evaluating the role of a board-certified oncology pharmacist in the head and neck oncology clinic at an academic, comprehensive cancer center from April 2017 through March 2018. The primary objective of the study was to describe the types of interventions made by the oncology pharmacists. Secondary objectives included quantifying time spent on patient education and number of prescriptions sent to pharmacies.
The pharmacist had 873 encounters with 151 patients, resulting in 2080 interventions. Approximately 57% of the interventions were performed in the clinic. Patient education (58%), facilitation of new prescriptions or refill requests (49.9%), and supportive care management (32.6%) were the most frequent interventions. The oncology pharmacist spent 154.1 h on patient education and sent 811 prescriptions to pharmacies, with 63.6% of prescriptions sent to the institution's cancer center pharmacy.
The incorporation of an oncology pharmacist in the HNC team optimized patient care through comprehensive and timely interventions across the care continuum. Our study is the first to highlight the vital role oncology pharmacists have in improving the overall quality of care of HNC patients. Future directions include exploring the impact of oncology pharmacist interventions on select Quality Oncology Practice Initiative measures by the American Society of Clinical Oncology.
头颈癌(HNC)是一组复杂且异质性的癌症,在整个护理过程中通常需要多学科方法。肿瘤药师具备独特的资质,能在多学科团队中发挥关键作用,并提供专业护理以优化药物治疗。
这是一项回顾性病历审查,评估一名获得董事会认证的肿瘤药师在2017年4月至2018年3月期间在一家学术性综合癌症中心的头颈肿瘤诊所中的作用。该研究的主要目的是描述肿瘤药师所进行的干预类型。次要目的包括量化花在患者教育上的时间以及发送到药房的处方数量。
药师与151名患者进行了873次接触,产生了2080次干预。大约57%的干预是在诊所进行的。患者教育(58%)、促进新处方或续方请求(49.9%)以及支持性护理管理(32.6%)是最常见的干预措施。肿瘤药师花了154.1小时进行患者教育,并向药房发送了811张处方,其中63.6%的处方发送到了该机构的癌症中心药房。
在头颈癌团队中纳入肿瘤药师,通过在整个护理过程中进行全面且及时的干预,优化了患者护理。我们的研究首次强调了肿瘤药师在提高头颈癌患者整体护理质量方面的重要作用。未来的方向包括探索肿瘤药师干预对美国临床肿瘤学会选定的肿瘤学质量实践倡议措施的影响。